Fritz Kunz new Numab chair
This article was originally published in Scrip
Executive Summary
Swiss biotech company Numab has appointed Dr Fritz Kunz chair of the board. Dr Kunz served as CEO of Institute Straumann from 1994-1998, and was chair of Speedel from 2000 until 2008 when it was acquired by Novartis. Currently he is also chair of Kuros and a board member at Sentec.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.